Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Emergent Biosolutions
(NY:
EBS
)
10.69
+2.03 (+23.44%)
Streaming Delayed Price
Updated: 3:34 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Emergent Biosolutions
< Previous
1
2
3
4
Next >
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
October 19, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
October 02, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
August 30, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
August 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
August 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
July 31, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
July 25, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
July 20, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces CEO Transition
June 27, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
May 15, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
May 11, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Financial Results For First Quarter 2023
May 09, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
April 19, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
March 29, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
February 27, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
February 15, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
February 15, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
February 06, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
January 18, 2023
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
January 09, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
January 05, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
December 06, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
November 14, 2022
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
November 08, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
November 01, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
October 27, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
October 18, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
September 21, 2021
From
Shuman, Glenn & Stecker
Via
Business Wire
NYSE:EBS Long Term Investor Alert: Investigation of Potential Wrongdoing at Emergent BioSolutions Inc
August 23, 2021
San Diego, CA -- (SBWIRE) -- 08/23/2021 -- Certain directors of Emergent BioSolutions Inc are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders
June 23, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.